BVF group (NASDAQ: KYMR) reports 6,068-share Kymera option grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Kymera Therapeutics, Inc. had a group of BVF-affiliated reporting persons update their ownership in its securities. The only new transaction was an indirect grant of 6,068 stock options linked to common stock at an exercise price of $99.8700 per share.
These options expire on June 23, 2036 and vest in full on the earlier of June 24, 2027 or the date of Kymera’s next annual stockholder meeting. The filing also restates existing holdings in common shares, previously granted stock options, and pre-funded warrants that are exercisable at $0.0001 per share and do not expire.
Positive
- None.
Negative
- None.
Insider Trade Summary
17 transactions reported
Mixed
17 txns
Insider
BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N
Role
null | null | null | null | null | null | null | null | null | null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 6,068 | $0.00 | -- |
| holding | Pre-Funded Warrants to Purchase Common Stock | -- | -- | -- |
| holding | Pre-Funded Warrants to Purchase Common Stock | -- | -- | -- |
| holding | Pre-Funded Warrants to Purchase Common Stock | -- | -- | -- |
| holding | Pre-Funded Warrants to Purchase Common Stock | -- | -- | -- |
| holding | Pre-Funded Warrants to Purchase Common Stock | -- | -- | -- |
| holding | Pre-Funded Warrants to Purchase Common Stock | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock, $0.0001 par value | -- | -- | -- |
| holding | Common Stock, $0.0001 par value | -- | -- | -- |
| holding | Common Stock, $0.0001 par value | -- | -- | -- |
| holding | Common Stock, $0.0001 par value | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 6,068 shares (Indirect, See footnote);
Pre-Funded Warrants to Purchase Common Stock — 201,546 shares (Direct, null);
Pre-Funded Warrants to Purchase Common Stock — 27,797 shares (Indirect, See footnote);
Common Stock, $0.0001 par value — 2,798,795 shares (Direct, null);
Common Stock, $0.0001 par value — 130,645 shares (Indirect, See footnote)
Footnotes (1)
- This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein. Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF. Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS. Securities held in a certain Partners managed account (the "Partners Managed Account"). Partners may be deemed to have indirect beneficial ownership of the securities of the Issuer held by the Partners Managed Account for purposes of Rule 16a-1(a)(2) because the securities account for more than 10% of the market value of the portfolio of the Partners Managed Account as of the reporting date. Partners, as the investment manager of the Partners Managed Account, may be deemed to beneficially own the securities held by the Partners Managed Account. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Account. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Account. Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders. The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to certain conditions and limitations, and do not expire. The shares subject to the option have fully vested.
Key Figures
New option grant size: 6,068 options
New option exercise price: $99.8700/share
New option expiration: June 23, 2036
+4 more
7 metrics
New option grant size
6,068 options
Grant of stock options reported for BVF-affiliated holders
New option exercise price
$99.8700/share
Exercise price for 6,068 newly granted stock options
New option expiration
June 23, 2036
Expiration date of the 6,068 newly granted stock options
Option vesting date
June 24, 2027
Latest vesting date; earlier vesting at next annual meeting
Existing option tranche
40,127 options at $20.0000
Indirect stock option position expiring August 19, 2030
Largest pre-funded warrant block
550,425 underlying shares
Direct pre-funded warrants exercisable at $0.0001/share, no expiry
Common stock holding example
2,798,795 shares
Direct common stock holding after transactions for one entity
Key Terms
Pre-Funded Warrants to Purchase Common Stock, Stock Option (Right to Buy), Section 13(d) group, pecuniary interest, +1 more
5 terms
Pre-Funded Warrants to Purchase Common Stock financial
"Pre-Funded Warrants to Purchase Common Stock, exercise price $0.0001, do not expire"
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with underlying Kymera common stock"
Section 13(d) group regulatory
"Each of the Reporting Persons is a member of a Section 13(d) group."
pecuniary interest financial
"Each of the Reporting Persons disclaims beneficial ownership except to the extent of his or its pecuniary interest therein."
Rule 16a-1(a)(2) regulatory
"Partners Managed Account for purposes of Rule 16a-1(a)(2) because the securities account for more than 10%."
FAQ
What insider activity did BVF-affiliated entities report in Kymera Therapeutics (KYMR)?
BVF-affiliated reporting persons reported an indirect grant of 6,068 stock options tied to Kymera common stock. The filing also updated existing holdings in common shares, previously issued options, and pre-funded warrants without showing any open-market purchases or sales.
What is the exercise price and expiration for the new Kymera stock options?
The newly granted 6,068 stock options carry an exercise price of $99.8700 per share and expire on June 23, 2036. They provide long-dated exposure to Kymera’s equity for the BVF-associated reporting persons.
When do the newly granted Kymera options to BVF-affiliated entities vest?
The 6,068 options vest in full on the earlier of June 24, 2027 or the date of Kymera’s next annual stockholder meeting. This time-based vesting schedule aligns the economic benefit with continued board service and corporate governance milestones.
What other derivative positions in Kymera does the BVF group report holding?
The BVF reporting group lists multiple stock options over 16,000 to 40,127 underlying shares with exercise prices from $14.1800 to $49.1000, plus pre-funded warrants exercisable at $0.0001 per share, many with substantial underlying share counts.